Patient Management

2074 soru

Tüm türler2,074 Çoktan seçmeli1,048 Çoklu seçim393 Eşleştirme221 Sıralama412

Soru 2001Soru →

A $29$ -year-old woman is evaluated in the neurology clinic to discuss disease-modifying therapy for her relapsing-remitting multiple sclerosis. She was diagnosed $2$ years ago and has experienced $3$ clinical relapses over the past year despite consistent compliance with glatiramer acetate therapy. Magnetic resonance imaging of the brain and cervical spine reveals multiple new gadolinium-enhancing lesions. After a thorough discussion of risks and benefits, the decision is made to transition her to oral fingolimod.

Based on the specific mechanism of action and adverse effect profile of fingolimod, which of the following baseline and ongoing monitoring protocols are strictly required for this patient? (Select $2$ answers)

Geçerli olan tümünü seçin

Continuous electrocardiographic monitoring for

6

hours following the first dose

Baseline and periodic dilated ophthalmologic examinations

Serial serum anti-JC virus antibody index testing

Routine assessment of left ventricular ejection fraction via echocardiography

Monthly testing of serum thyroid-stimulating hormone levels

Cevabı ve açıklamayı göster

Cevap: Continuous electrocardiographic monitoring for $6$ hours following the first dose; Baseline and periodic dilated ophthalmologic examinations

Cevap

Continuous electrocardiographic monitoring for

6

hours following the first dose AND Baseline and periodic dilated ophthalmologic examinations

Fingolimod acts as a sphingosine-1-phosphate (S1P) receptor modulator. Because S1P receptors are present in both lymph nodes and atrial myocytes, initial binding causes a transient decrease in heart rate and potential atrioventricular conduction delays. Thus, continuous electrocardiographic monitoring for

6

hours post-dose is required. Furthermore, the drug alters vascular permeability, leading to a well-documented risk of fingolimod-associated macular edema (FAME). This strictly mandates a baseline dilated ophthalmologic evaluation and follow-up at

3

4

months.

Adım Adım Çözüm

Identify the specific pharmacological agent and its drug class.

The prescribed drug is fingolimod, which acts as a sphingosine-1-phosphate (S1P) receptor modulator.

Different multiple sclerosis therapies have entirely distinct mechanisms of action that dictate their unique safety and monitoring protocols.

Recall the mechanism-specific adverse effects associated with fingolimod.

Fingolimod causes early bradycardia/conduction blocks (due to S1P receptors in the heart) and increases vascular permeability leading to macular edema.

Regulatory guidelines and standard of care require monitoring to prevent severe outcomes from these specific anticipated side effects.

Match the required surveillance protocols to the identified adverse effects.

The cardiac risk necessitates

6

-hour continuous electrocardiography upon initiation, and the macular risk necessitates baseline and periodic dilated ophthalmologic examinations.

These protocols directly mitigate the morbidity of first-dose bradycardia and fingolimod-associated macular edema (FAME).

Rule out monitoring parameters associated with other disease-modifying therapies.

JC virus testing, echocardiography, and monthly TSH are excluded as they are indicated for natalizumab, mitoxantrone, and alemtuzumab, respectively.

Applying the wrong screening protocol exposes the patient to unnecessary testing while missing critical drug-specific toxicities.

Anahtar Kavram

Patients initiated on fingolimod for multiple sclerosis require first-dose continuous electrocardiography for

6

hours to monitor for bradyarrhythmias, and baseline/periodic ophthalmologic exams to monitor for macular edema.

Soru 2002Soru →

A $65$ -year-old male presents to the clinic for a routine follow-up evaluation. He has a history of heart failure with reduced ejection fraction (left ventricular ejection fraction of $35\%$ ). Two weeks ago, spironolactone was added to his medical regimen, which already included sacubitril-valsartan, carvedilol, and dapagliflozin. The patient states he feels well and reports no shortness of breath, orthopnea, or lower extremity edema. His vital signs are within normal limits.

Laboratory studies obtained today show:
Serum sodium: $138 \text{ mEq/L}$
Serum potassium: $5.3 \text{ mEq/L}$ (Baseline: $4.5 \text{ mEq/L}$ prior to spironolactone)
Blood urea nitrogen: $22 \text{ mg/dL}$
Serum creatinine: $1.4 \text{ mg/dL}$ (Baseline: $1.2 \text{ mg/dL}$ )

Which of the following is the most appropriate next step in the management of this patient?

Continue the current medication regimen without changes

Discontinue spironolactone immediately

Discontinue sacubitril-valsartan immediately

Admit the patient to the hospital for continuous telemetry monitoring

Order a renal Doppler ultrasound

Cevabı ve açıklamayı göster

Cevap: Continue the current medication regimen without changes

Cevap

Continue the current medication regimen without changes

The correct answer is to continue the current medication regimen without changes. This patient with heart failure with reduced ejection fraction (HFrEF) recently started spironolactone. Mineralocorticoid receptor antagonists (MRAs) like spironolactone, as well as angiotensin receptor-neprilysin inhibitors (ARNIs) like sacubitril-valsartan, reduce renal perfusion pressure and decrease potassium excretion. It is a widely accepted clinical standard that a rise in serum creatinine of up to

30\%

from baseline and a mild increase in serum potassium (up to

5.5 \text{ mEq/L}

) are anticipated and acceptable physiological responses to these agents. Because the patient's creatinine increased by less than

20\%

(from

1.2

1.4 \text{ mg/dL}

) and his potassium is

5.3 \text{ mEq/L}

without symptoms, the medications should be continued to maintain their significant mortality benefit.

Adım Adım Çözüm

Evaluate the patient's clinical status and laboratory results.

The patient is asymptomatic. Potassium is mildly elevated at

5.3 \text{ mEq/L}

and creatinine has increased from

1.2 \text{ mg/dL}

1.4 \text{ mg/dL}

To determine if the abnormalities represent a life-threatening emergency or an expected pharmacologic effect.

Assess the expected physiological effects of guideline-directed medical therapy (GDMT) for heart failure.

Spironolactone and sacubitril-valsartan can both cause mild hyperkalemia and a modest rise in serum creatinine due to their effects on the renin-angiotensin-aldosterone system.

To avoid prematurely discontinuing mortality-reducing therapies.

Determine the safety thresholds for continuing therapy.

A creatinine increase of up to

30\%

from baseline and a serum potassium of up to

5.5 \text{ mEq/L}

are considered acceptable parameters for continued therapy.

This patient's creatinine increased by roughly

16\%

and potassium is well below the

5.5 \text{ mEq/L}

threshold, indicating the regimen can be safely continued.

Anahtar Kavram

Expected physiological responses to renin-angiotensin-aldosterone system (RAAS) inhibitors in heart failure management

Tahmini Süre:1m 30s

Soru 2003Soru →

A 68-year-old woman presents to the clinic for an annual health maintenance examination. She feels well and has no new symptoms. Her past medical history is notable for a total abdominal hysterectomy and bilateral salpingo-oophorectomy at age 62. The surgical pathology at that time revealed cervical intraepithelial neoplasia (CIN) 3 with negative surgical margins. She has not undergone any further gynecologic evaluation since her postoperative period. She has never smoked and consumes alcohol occasionally. Her family history is noncontributory. Screening mammography performed 1 year ago was negative for malignancy. A screening colonoscopy and a dual-energy x-ray absorptiometry (DXA) scan performed at age 65 were both normal. Vital signs and physical examination today are unremarkable. Which of the following is the most appropriate next step in preventive screening for this patient?

Cytology and high-risk human papillomavirus testing of the vaginal cuff

Reassurance that no routine cancer screening is currently indicated

Annual fecal immunochemical testing

Repeat dual-energy x-ray absorptiometry scan

Serum CA-125 measurement and pelvic ultrasonography

Cevabı ve açıklamayı göster

Cevap: Cytology and high-risk human papillomavirus testing of the vaginal cuff

Cevap

The correct answer is cytology and high-risk human papillomavirus testing of the vaginal cuff.

According to the United States Preventive Services Task Force (USPSTF) and the American Society for Colposcopy and Cervical Pathology (ASCCP), routine cervical cancer screening can be discontinued in women over age 65 who have had adequate prior screening, and in women of any age who have undergone a total hysterectomy for benign disease. However, a critical exception exists for women with a history of cervical intraepithelial neoplasia (CIN) grade 2, CIN 3, or cervical cancer. These patients remain at elevated risk for vaginal intraepithelial neoplasia and must continue to receive routine screening of the vaginal cuff for at least 20 years after the spontaneous regression or appropriate management of the disease. Because this patient was treated for CIN 3 at age 62, she must continue screening until age 82. Since she has had no screening in the 6 years following her surgery, cytology and high-risk HPV testing of the vaginal cuff is the most appropriate next step.

Adım Adım Çözüm

Evaluate the patient's age and surgical history against general cervical cancer screening guidelines.

The patient is 68 years old and had a total hysterectomy. Generally, screening ceases at age 65 or after removal of the cervix for benign indications.

To determine if standard age or surgical cutoffs apply.

Assess the specific indication for the patient's hysterectomy.

The hysterectomy was performed for high-grade cervical dysplasia (CIN 3).

Surgical indication dictates whether exceptions to the standard cessation rules apply.

Apply the exception guidelines for high-grade cervical dysplasia.

Patients treated for CIN 2, CIN 3, or cervical cancer must continue screening for 20 years post-treatment, utilizing the vaginal cuff if the cervix was removed.

CIN 3 carries a long-term risk of recurrence or progression at the vaginal apex.

Review the status of other preventive screenings (colon, breast, bone density).

Mammogram is up to date (due every 2 years). Colonoscopy is up to date (due in 10 years). DXA is up to date (due in 10-15 years for normal results).

To rule out other competing indications for immediate preventive interventions.

Anahtar Kavram

Cervical cancer screening must continue for 20 years following treatment for CIN 2, CIN 3, or cervical cancer, even if this extends screening beyond age 65 or follows a total hysterectomy.

Soru 2004Soru →

An otherwise healthy $71$ -year-old female is evaluated in the emergency department for severe unilateral head pain that began $3$ days ago. She notes exquisite tenderness when brushing her hair and describes an aching fatigue in her jaw muscles during meals. Blood tests demonstrate an erythrocyte sedimentation rate (ESR) of $98 \text{ mm/h}$ and a C-reactive protein (CRP) of $45 \text{ mg/L}$ . Order the following therapeutic and surveillance interventions in the correct chronological sequence for the longitudinal management of this condition.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence begins with immediate glucocorticoid administration to prevent irreversible vision loss. Second, a temporal artery biopsy is obtained to confirm the diagnosis (which remains accurate even after days of steroid use). Third, the patient is monitored clinically and with serial inflammatory markers to guide a gradual steroid taper. Fourth, if disease relapse occurs during the taper, a steroid-sparing agent like tocilizumab is initiated. Finally, long-term monitoring must include imaging to evaluate for late-onset aortic aneurysms.

The standard of care for suspected giant cell arteritis dictates that empiric high-dose glucocorticoids must be initiated instantly to prevent blindness. A temporal artery biopsy is then scheduled within 1-2 weeks. After stabilization, the treatment evaluation phase relies on serial ESR/CRP and symptom checks to carefully taper the steroids over many months. If relapses occur, targeted biologic therapy is introduced. Lastly, because of the disease's pathophysiology, long-term structural monitoring for aortic aneurysms is required indefinitely.

Adım Adım Çözüm

Administer high-dose systemic glucocorticoids.

Prevents anterior ischemic optic neuropathy and irreversible blindness.

In highly suspected giant cell arteritis, empiric treatment is a medical emergency and must precede definitive diagnostic testing to preserve vision.

Obtain a temporal artery biopsy.

Provides definitive histological confirmation of arteritis.

Long-term steroid therapy carries heavy morbidity. A tissue diagnosis is required to justify long-term exposure, and the biopsy remains diagnostic up to 2 weeks after starting steroids.

Monitor serial clinical symptoms and acute-phase reactants.

Guides the progressive tapering of glucocorticoids.

Steroids must be slowly tapered over months to avoid relapses while minimizing the risk of osteoporosis, diabetes, and infections. Monitoring ESR and CRP helps ensure the disease remains suppressed.

Initiate a steroid-sparing immunomodulator.

Achieves disease control while allowing for further steroid reduction.

If the patient fails the steroid taper (relapse of headache, jaw claudication, or rising ESR/CRP), an agent like tocilizumab is indicated to achieve remission.

Perform annual imaging surveillance of the aorta.

Detects asymptomatic large-vessel complications.

Giant cell arteritis involves the aorta and its major branches in up to 30% of patients, presenting a lifelong risk for aortic aneurysm and dissection that requires structured monitoring.

Anahtar Kavram

Chronological treatment sequencing, tapering, and surveillance in Giant Cell Arteritis

Soru 2005Soru →

For each of the following ambulatory patients presenting for routine care, select the most appropriate, guideline-concordant preventive intervention or screening strategy indicated by their unique risk factors.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Cevabı ve açıklamayı göster

Cevap

The correct matches align each patient with their specific USPSTF-indicated preventive intervention: the 45-year-old with overweight requires diabetes screening, the pregnant patient with SLE requires aspirin prophylaxis, the immigrant from an endemic region requires HBV screening, and the former smoker requires lung cancer screening.

Each clinical profile possesses a distinct set of risk factors that unambiguously triggers one specific USPSTF Grade A or B recommendation among the available choices. The matching relies on precise cutoffs for age, BMI, geographic prevalence, and smoking history.

Adım Adım Çözüm

Analyze the 45-year-old woman's profile.

Identify her BMI of 28 kg/m² as overweight, which along with her age (35-70 years range), meets the USPSTF criteria for type 2 diabetes screening.

Age and BMI are the primary independent triggers for routine glycemic screening in asymptomatic adults.

Evaluate the 28-year-old pregnant patient's risk profile.

Recognize systemic lupus erythematosus as a major high-risk condition for preeclampsia, indicating the need for low-dose aspirin starting after 12 weeks of gestation.

Preventing preeclampsia is critical in high-risk pregnancies, and aspirin is the standard guideline-concordant prophylactic intervention.

Assess the 35-year-old immigrant's background.

Determine that birth in sub-Saharan Africa (an endemic region with prevalence ≥ 2%) places him at high risk for hepatitis B, requiring one-time screening.

Targeted screening based on geographic origin identifies chronic asymptomatic carriers who require monitoring or treatment.

Review the 55-year-old man's smoking history.

Calculate that his 25 pack-year history and 8-year quit duration fall within the USPSTF parameters (50-80 years old, ≥20 pack-years, quit within 15 years) for low-dose computed tomography.

Annual LDCT is the only proven modality to reduce lung cancer mortality in appropriately selected high-risk individuals.

Anahtar Kavram

Application of United States Preventive Services Task Force (USPSTF) guidelines based on specific patient demographics, comorbidities, and social histories.

Soru 2006Soru →

An established $58$ -year-old male patient comes to the primary care clinic to review his recent laboratory results. Four weeks prior, he was noted to have a blood pressure of $154/92$ mmHg and persistent microalbuminuria. At that time, lisinopril therapy was prescribed. During today's visit, he reports feeling well without any dizziness, peripheral edema, or changes in urinary output. His current blood pressure is $128/78$ mmHg. A comparison of his laboratory panels is provided below:

Parameter	Four Weeks Ago	Current Visit
Blood urea nitrogen	$16$ mg/dL	$22$ mg/dL
Serum creatinine	$1.2$ mg/dL	$1.5$ mg/dL
Serum potassium	$4.1$ mEq/L	$4.8$ mEq/L

Which of the following is the most appropriate next step in the management of this patient?

Maintain the present dosage of lisinopril and schedule routine follow-up

Halt lisinopril therapy and begin treatment with amlodipine

Discontinue lisinopril and substitute with valsartan

Obtain a bilateral renal artery duplex ultrasound

Add spironolactone to provide additional renal protection

Cevabı ve açıklamayı göster

Cevap: Maintain the present dosage of lisinopril and schedule routine follow-up

Cevap

Maintain the present dosage of lisinopril and schedule routine follow-up.

The correct course of action is to maintain the present dosage of lisinopril and schedule a routine follow-up. ACE inhibitors prevent the conversion of Angiotensin I to Angiotensin II. Because Angiotensin II normally preferentially constricts the efferent arteriole of the glomerulus, blocking its action leads to efferent arteriolar vasodilation. This lowers intraglomerular hydrostatic pressure, which is highly beneficial for slowing the progression of diabetic nephropathy. However, the drop in intraglomerular pressure correspondingly causes a mild decrease in the Glomerular Filtration Rate (GFR), which manifests clinically as an acute increase in serum creatinine. Clinical guidelines establish that an increase in serum creatinine of up to

30\%

from baseline within the first several weeks of initiating an ACE inhibitor or ARB is a safe, expected hemodynamic response. In this patient, the creatinine increased from

1.2

mg/dL to

1.5

mg/dL, which is exactly a

25\%

increase. Since his potassium remains within the normal range (

4.8

mEq/L) and his blood pressure is well controlled, the medication should be continued to preserve its renoprotective benefits.

Adım Adım Çözüm

Evaluate the magnitude of the serum creatinine increase from the baseline laboratory values.

The serum creatinine rose from

1.2

mg/dL to

1.5

mg/dL, which represents exactly a

25\%

absolute increase.

Guidelines state that a rise in serum creatinine of

\leq 30\%

following the initiation of an ACE inhibitor or ARB is a normal and acceptable physiologic response.

Assess the serum potassium level and overall clinical status to ensure there are no life-threatening complications.

The patient's potassium is

4.8

mEq/L (within normal limits), and his blood pressure has successfully improved to

128/78

mmHg without hypotensive symptoms.

Significant hyperkalemia (

> 5.5

mEq/L) or symptomatic hypotension would necessitate a dose reduction or discontinuation of the therapy.

Determine the appropriate management intervention based on the physiological interpretation of the labs.

Because the laboratory changes reflect expected efferent arteriolar vasodilation rather than acute tubular necrosis or true kidney injury, no changes to the medication are required.

Continuing the current medication allows the patient to maintain the cardiovascular and renoprotective benefits of ACE inhibition.

Anahtar Kavram

Monitoring ACE inhibitor therapy initiation

Soru 2007Soru →

An established patient, a 63-year-old biological male, schedules an ambulatory telehealth appointment to discuss his health maintenance plan before a planned cross-country relocation. His past medical history is significant for chronic obstructive pulmonary disease (COPD), obesity (BMI 33 kg/m²), and a prior hepatitis C infection that was successfully treated with direct-acting antivirals five years ago. He currently smokes half a pack of cigarettes daily and has done so since age 18. Medical records indicate he underwent a screening colonoscopy at age 54, which was unremarkable. A lipid panel and hemoglobin A1c obtained last week are within normal limits. He received an annual influenza vaccination two months ago and a Tdap booster three years ago. He has not received any other adult vaccines. Which of the following preventive interventions are indicated for this patient at this time? (Select all that apply)

Geçerli olan tümünü seçin

Annual low-dose computed tomography of the chest

Administration of a 20-valent pneumococcal conjugate vaccine

Screening ultrasound of the abdominal aorta

Repeat screening colonoscopy

Hepatitis C virus antibody testing

Cevabı ve açıklamayı göster

Cevap: Annual low-dose computed tomography of the chest; Administration of a 20-valent pneumococcal conjugate vaccine

Cevap

The indicated interventions for this patient are annual low-dose computed tomography of the chest and administration of a 20-valent pneumococcal conjugate vaccine.

The correct preventive interventions include low-dose computed tomography (LDCT) of the chest and a pneumococcal conjugate vaccine. LDCT is recommended by the USPSTF for adults aged 50 to 80 years with at least a 20 pack-year smoking history who currently smoke or have quit within the last 15 years; this patient meets all criteria with a 22.5 pack-year history. Additionally, the ACIP recommends pneumococcal vaccination for all adults aged 65 and older, but also for adults aged 19 to 64 years with specific underlying medical conditions. The patient's chronic obstructive pulmonary disease (COPD) qualifies him for the pneumococcal vaccine prior to age 65.

Adım Adım Çözüm

Calculate the patient's smoking pack-year history.

The patient has smoked 0.5 packs per day for 45 years (from age 18 to 63), resulting in a 22.5 pack-year history.

Accurate pack-year calculation is necessary to determine eligibility for lung cancer screening.

Evaluate the patient for lung cancer screening criteria.

The patient is between 50-80 years old, has a >20 pack-year smoking history, and is a current smoker. Low-dose computed tomography of the chest is indicated.

USPSTF guidelines mandate these specific demographic and historical criteria for annual lung cancer screening.

Assess the patient's vaccination needs based on age and comorbidities.

Although under 65, the patient has COPD, which is a qualifying underlying medical condition for pneumococcal vaccination. The 20-valent pneumococcal conjugate vaccine is indicated.

ACIP guidelines require risk-stratification for adults aged 19-64 to determine pneumococcal vaccine eligibility.

Analyze age and timeline criteria for the remaining screening options.

Abdominal aortic aneurysm screening is deferred until age 65. The next screening colonoscopy is deferred until age 64 (10 years after a normal exam).

Preventive screening must strictly adhere to upper and lower age limits as well as established testing intervals.

Determine the appropriate management for the patient's prior hepatitis C infection.

Routine HCV antibody testing is excluded because his antibodies will remain positive for life post-treatment.

Understanding the serological footprint of treated infectious diseases prevents unnecessary and confusing downstream testing.

Anahtar Kavram

Application of age-specific, interval-specific, and comorbidity-modified preventive screening and immunization guidelines.

Soru 2008Soru →

During a comprehensive health evaluation, a 54-year-old man establishes care with a new physician. He reports no acute complaints and notes that he exercises moderately three times a week. His medical history includes diet-controlled type 2 diabetes mellitus. He smoked one and a half packs of cigarettes daily for 20 years, equating to a 30 pack-year smoking history, but completely ceased smoking 12 years ago. A review of his previous medical records reveals a structurally normal colon on a screening colonoscopy performed at age 48 and a negative hepatitis C antibody test three years ago. His vital signs are within normal limits, and his physical examination is unremarkable. In addition to reviewing his vaccinations, which of the following preventive interventions is most strongly indicated for this patient?

Routine resting electrocardiography

One-time ultrasound of the abdominal aorta

Annual low-dose computed tomography of the chest

Repeat screening colonoscopy

Carotid duplex ultrasonography

Cevabı ve açıklamayı göster

Cevap: Annual low-dose computed tomography of the chest

Cevap

Annual low-dose computed tomography of the chest

The correct answer accurately identifies that the patient meets the established criteria for lung cancer screening. Major guidelines recommend annual screening for lung cancer using low-dose computed tomography (LDCT) in adults aged 50 to 80 years who have a 20 pack-year smoking history and either currently smoke or have quit within the past 15 years. This 54-year-old patient has a 30 pack-year history and quit 12 years ago, making LDCT the most strongly indicated preventive intervention for him today.

Adım Adım Çözüm

Analyze the patient's demographic and risk factor profile.

The patient is a 54-year-old man with a 30 pack-year smoking history who quit 12 years ago, and had a normal screening colonoscopy 6 years ago.

Accurate assessment of age, prior testing dates, and specific behavioral risk factors dictates the currently indicated preventive screening.

Determine eligibility for lung cancer screening.

The patient is between 50 and 80 years old, has at least a 20 pack-year smoking history, and quit within the last 15 years.

Current USPSTF guidelines recommend annual low-dose CT for this specific demographic to reduce lung cancer mortality.

Evaluate the indications for the alternative screening modalities presented.

The patient does not meet age criteria for AAA screening, is not yet due for a repeat colonoscopy, and asymptomatic cardiovascular screening is not recommended.

Applying age limits and appropriate screening intervals prevents overtesting, unnecessary radiation exposure, and harmful downstream invasive procedures.

Anahtar Kavram

Evidence-based preventive screening guidelines for adults, specifically focusing on lung cancer screening criteria and appropriate intervals for colon cancer screening.

Soru 2009Soru →

During multidisciplinary ward rounds, the care team evaluates a 58-year-old man who was admitted 48 hours ago for an unprovoked subsegmental pulmonary embolism and a right popliteal deep vein thrombosis. Upon admission, the patient was hemodynamically stable and was initiated on a therapeutic dose of apixaban. His medical history is notable for essential hypertension, hyperlipidemia, and focal impaired awareness seizures. His home medications include lisinopril, atorvastatin, and carbamazepine. He has been seizure-free on his current carbamazepine regimen for the past six years. Current vital signs are within normal limits, and he is saturating at 97% on room air. Laboratory results demonstrate a serum creatinine of 1.0 mg/dL, with normal hepatic and coagulation panels. The clinical pharmacist expresses concern regarding the patient's current antithrombotic therapy due to a major pharmacokinetic incompatibility. Which of the following is the most appropriate pharmacologic intervention?

Continue the current regimen and add oral clopidogrel

Discontinue apixaban, begin therapeutic enoxaparin, and initiate warfarin

Discontinue apixaban and begin rivaroxaban

Discontinue carbamazepine, begin levetiracetam, and continue apixaban

Continue the current regimen and observe closely for signs of recurrent thrombosis

Cevabı ve açıklamayı göster

Cevap: Discontinue apixaban, begin therapeutic enoxaparin, and initiate warfarin

Cevap

The most appropriate intervention is to discontinue apixaban, start therapeutic enoxaparin, and initiate warfarin therapy.

The correct answer addresses the absolute contraindication between apixaban and carbamazepine. Carbamazepine is a potent inducer of CYP3A4 and P-glycoprotein, the primary metabolic and efflux pathways for apixaban. Co-administration results in rapid apixaban clearance, subtherapeutic anticoagulation, and a high risk of recurrent pulmonary embolism. Because there is no validated protocol to dose-adjust DOACs based on serum levels, all DOACs must be avoided. The standard of care is to transition the patient to warfarin. Although carbamazepine also induces warfarin metabolism, warfarin therapy is uniquely guided by routine INR monitoring, allowing the physician to safely titrate the dose upward until therapeutic efficacy (INR 2.0-3.0) is achieved. Because warfarin takes several days to become therapeutic, an immediate bridge with low-molecular-weight heparin (enoxaparin)—which is renally cleared and completely unaffected by hepatic enzyme induction—is required.

Adım Adım Çözüm

Identify the critical drug-drug interaction in the patient's regimen.

Carbamazepine is a strong inducer of Cytochrome P450 3A4 (CYP3A4) and P-glycoprotein (P-gp). Apixaban is a major substrate for both pathways.

Recognizing this interaction is the first step in assessing antithrombotic efficacy.

Determine the clinical consequence of this interaction.

Strong induction of CYP3A4 and P-gp drastically increases the clearance of apixaban, leading to subtherapeutic serum concentrations and high risk of recurrent venous thromboembolism (VTE).

DOACs do not have a validated routine laboratory test to monitor therapeutic efficacy and adjust doses.

Evaluate alternative antithrombotic strategies that bypass or manage the induction.

Other DOACs (rivaroxaban, dabigatran) share similar metabolic pathways and are also contraindicated. Warfarin metabolism (CYP2C9/3A4) is also induced by carbamazepine, but warfarin can be safely used because its dose is titrated based on a direct measure of efficacy (INR).

Selecting an agent that allows for objective therapeutic monitoring ensures the patient receives adequate anticoagulation.

Formulate the exact transition plan.

Start a low-molecular-weight heparin (enoxaparin), which is renally cleared and unaffected by CYP/P-gp induction, to provide immediate protection while titrating warfarin to a target INR of 2.0-3.0.

Bridging is required because warfarin takes several days to reach therapeutic levels, especially in the setting of hepatic enzyme induction.

Anahtar Kavram

Direct oral anticoagulants (DOACs) are strictly contraindicated with strong CYP3A4 and P-glycoprotein inducers (e.g., carbamazepine, phenytoin, rifampin); patients require transitioning to an LMWH bridge and warfarin, as warfarin can be titrated to a target INR.

Soru 2010Soru →

A 62-year-old man with recently diagnosed heart failure with reduced ejection fraction (LVEF 30%) comes to the clinic for a follow-up visit. He is currently asymptomatic at rest but experiences dyspnea with moderate exertion. His current medications include carvedilol and dapagliflozin. The physician decides to optimize his guideline-directed medical therapy by initiating sacubitril-valsartan and spironolactone. Baseline laboratory studies show a serum creatinine of 1.1 mg/dL and a serum potassium of 4.2 mEq/L. Which of the following are necessary and appropriate ongoing monitoring and treatment evaluation strategies for this patient? (Select all that apply)

Geçerli olan tümünü seçin

Assessment of serum potassium and creatinine within 1 to 2 weeks of initiating the new medications

Utilization of N-terminal pro-B-type natriuretic peptide (NT-proBNP) rather than B-type natriuretic peptide (BNP) for future biomarker evaluation

Monitoring of serial B-type natriuretic peptide (BNP) levels every 3 months to evaluate the therapeutic response to sacubitril-valsartan

Administration of an angiotensin-converting enzyme (ACE) inhibitor concurrently with the new regimen for a 36-hour transition period

Routine evaluation of left ventricular function using transesophageal echocardiography (TEE) every 6 months

Cevabı ve açıklamayı göster

Cevap: Assessment of serum potassium and creatinine within 1 to 2 weeks of initiating the new medications; Utilization of N-terminal pro-B-type natriuretic peptide (NT-proBNP) rather than B-type natriuretic peptide (BNP) for future biomarker evaluation

Cevap

The appropriate strategies include assessing serum potassium and creatinine within 1 to 2 weeks of initiation, and utilizing NT-proBNP rather than BNP for future biomarker evaluation.

Guideline-directed medical therapy for heart failure with reduced ejection fraction requires careful monitoring. Initiating an angiotensin receptor-neprilysin inhibitor (ARNI) and a mineralocorticoid receptor antagonist (MRA) increases the risk of hyperkalemia and renal insufficiency, necessitating a basic metabolic panel 1 to 2 weeks after initiation. Additionally, because the neprilysin inhibitor (sacubitril) prevents the degradation of B-type natriuretic peptide (BNP), BNP levels will be elevated regardless of the patient's volume status. Therefore, N-terminal pro-B-type natriuretic peptide (NT-proBNP), which is not degraded by neprilysin, must be used to evaluate therapeutic response.

Adım Adım Çözüm

Evaluate the mechanism and adverse effect profile of the newly initiated medications (sacubitril-valsartan and spironolactone).

Both medications can cause renal dysfunction and hyperkalemia. Furthermore, sacubitril inhibits the degradation of BNP.

Understanding the pharmacologic effects informs the necessary clinical and laboratory monitoring parameters.

Determine the optimal timeline for assessing renal function and electrolytes.

Serum potassium and creatinine should be evaluated 1 to 2 weeks after initiation.

This captures early changes in renal hemodynamics and potassium excretion, preventing severe hyperkalemia or acute kidney injury.

Identify the correct biomarker for ongoing evaluation of heart failure status in a patient taking an ARNI.

NT-proBNP must be used instead of BNP.

Because sacubitril directly elevates BNP levels, NT-proBNP is the only reliable natriuretic peptide marker in these patients.

Anahtar Kavram

Monitoring requirements for patients on guideline-directed medical therapy for heart failure include early assessment of renal function and potassium when initiating MRAs or ARNIs, and switching to NT-proBNP for biomarker monitoring because ARNIs falsely elevate BNP.

Tahmini Süre:1m 30s

Soru 2011Soru →

During a routine outpatient visit, a 32-year-old female reports a four-week history of unquenchable thirst and frequent urination. She states she has been drinking up to 6 liters of water daily and wakes up three to four times per night to void.

Her past psychiatric history is significant for severe, treatment-resistant bipolar I disorder. In her twenties, she experienced recurrent manic episodes with psychotic features that failed to respond to valproate and olanzapine. She was subsequently stabilized on lithium therapy three years ago. A recent psychiatric evaluation confirmed her mood is completely stable, and her psychiatrist strongly recommended avoiding any changes to her psychotropic regimen.

Vital signs are within normal limits. Physical examination reveals dry oral mucosa.

Laboratory data is as follows:

Laboratory Test	Result	Reference Range
Serum sodium	$146 \text{ mEq/L}$	$136-145 \text{ mEq/L}$
Serum potassium	$4.1 \text{ mEq/L}$	$3.5-5.0 \text{ mEq/L}$
Serum creatinine	$1.1 \text{ mg/dL}$	$0.6-1.2 \text{ mg/dL}$
Serum lithium	$0.9 \text{ mEq/L}$	$0.6-1.2 \text{ mEq/L}$
Urine specific gravity	$1.003$	$1.005-1.030$
Urine osmolality	$145 \text{ mOsm/kg}$	$500-850 \text{ mOsm/kg}$

Which of the following is the most appropriate next step in the management of this patient?

Initiate oral amiloride therapy

Advise strict restriction of daily free water intake

Administer intranasal desmopressin

Discontinue lithium and initiate carbamazepine

Order a supervised water deprivation test

Cevabı ve açıklamayı göster

Cevap: Initiate oral amiloride therapy

Cevap

The correct answer is to initiate oral amiloride therapy to manage the lithium-induced nephrogenic diabetes insipidus while maintaining her necessary psychiatric medication.

The correct approach is to prescribe amiloride. The patient has developed lithium-induced nephrogenic diabetes insipidus (NDI). Lithium enters the principal cells of the renal collecting duct through epithelial sodium channels (ENaC) and interferes with the normal intracellular response to antidiuretic hormone (ADH). Because this patient has a history of severe, treatment-resistant bipolar disorder that is currently stable, discontinuing lithium carries an unacceptably high risk of relapse. Amiloride is the treatment of choice in this situation; it is a potassium-sparing diuretic that blocks the ENaC channels, thereby preventing further lithium accumulation in the principal cells and partially restoring the kidneys' ability to concentrate urine.

Adım Adım Çözüm

Interpret the clinical presentation and laboratory data.

The patient has polyuria, polydipsia, high-normal serum sodium (

146 \text{ mEq/L}

), and dilute urine (osmolality

145 \text{ mOsm/kg}

) in the setting of chronic lithium use, confirming lithium-induced nephrogenic diabetes insipidus (NDI).

Establishing the correct diagnosis is the prerequisite for appropriate therapeutic modification.

Evaluate the viability of discontinuing the offending agent.

The patient has severe, treatment-resistant bipolar disorder that is only stable on lithium, and psychiatric consultation strongly advises against cessation.

Discontinuing lithium is generally the first-line treatment for lithium-induced NDI, but the risk of severe psychiatric relapse outweighs the renal benefits in this specific patient.

Determine the optimal pharmacologic adjunct to treat the side effect.

Amiloride is selected because it blocks ENaC channels in the collecting duct, preventing lithium entry into the principal cells.

This targeted intervention mitigates the toxicity and allows the patient to safely continue her essential psychiatric therapy.

Anahtar Kavram

Management of lithium-induced nephrogenic diabetes insipidus in patients requiring continued lithium therapy involves the addition of amiloride, which blocks lithium entry into the principal cells of the collecting duct.

Tahmini Süre:1m 30s

Soru 2012Soru →

Emergency medical services bring a 54-year-old male to the resuscitation bay for altered mental status and diffuse abdominal pain. His family members, who accompanied him, note that he has a history of severe alcohol use disorder and decompensated cirrhosis. Over the past 24 hours, he has become increasingly confused and feverish. He has not had any recent hematemesis or melena. His home medications include spironolactone, furosemide, propranolol, and lactulose.

Temperature is $38.4^\circ\text{C}$ ( $101.1^\circ\text{F}$ ), blood pressure is $92/56\text{ mm Hg}$ , pulse is $108/\text{min}$ , and respiratory rate is $18/\text{min}$ . Physical examination reveals scleral icterus, spider angiomas, and a distended, diffusely tender abdomen with shifting dullness. He is oriented only to person and exhibits asterixis.

Laboratory studies show:

Test	Result
Hemoglobin	$11.2\text{ g/dL}$
Leukocyte count	$12,500/\text{mm}^3$
Platelet count	$88,000/\text{mm}^3$
Sodium	$131\text{ mEq/L}$
Potassium	$4.2\text{ mEq/L}$
Blood urea nitrogen	$46\text{ mg/dL}$
Serum creatinine	$1.9\text{ mg/dL}$ (baseline $0.8\text{ mg/dL}$ )
Total bilirubin	$3.5\text{ mg/dL}$

Diagnostic paracentesis yields cloudy ascitic fluid with a total nucleated cell count of $800/\text{mm}^3$ and $80\%$ neutrophils.

Which of the following pharmacologic interventions are appropriate at this time? (Select all that apply)

Geçerli olan tümünü seçin

Initiate intravenous cefotaxime

Administer intravenous albumin

Discontinue oral propranolol

Initiate intravenous gentamicin

Initiate oral midodrine and subcutaneous octreotide

Maintain the current regimen of spironolactone and furosemide

Cevabı ve açıklamayı göster

Cevap: Initiate intravenous cefotaxime; Administer intravenous albumin; Discontinue oral propranolol

Cevap

The correct interventions are to initiate intravenous cefotaxime, administer intravenous albumin, and discontinue oral propranolol.

This patient presents with spontaneous bacterial peritonitis (SBP), complicated by acute kidney injury (AKI) and hypotension. Management requires a multi-pronged, simultaneous pharmacologic approach. First, empiric antibiotic therapy with a third-generation cephalosporin (such as cefotaxime or ceftriaxone) is the standard of care to target typical enteric pathogens. Second, this patient has a high risk of developing hepatorenal syndrome (HRS) due to an elevated creatinine (

>1.0\text{ mg/dL}

) and BUN (

>30\text{ mg/dL}

). In this setting, intravenous albumin administration (

1.5\text{ g/kg}

on day 1, followed by

1.0\text{ g/kg}

on day 3) is indicated to expand intravascular volume, prevent HRS, and reduce mortality. Finally, current clinical guidelines strongly recommend discontinuing non-selective beta-blockers (such as propranolol) and holding diuretics (spironolactone and furosemide) in patients with cirrhosis who develop SBP, sepsis, hypotension, or AKI. Continuing these agents can further reduce renal perfusion, exacerbate hypotension, and precipitate irreversible hepatorenal syndrome.

Adım Adım Çözüm

Diagnose Spontaneous Bacterial Peritonitis (SBP).

The absolute neutrophil count in the ascitic fluid is calculated as

800 \times 0.80 = 640/\text{mm}^3

An ascitic fluid neutrophil count

\ge 250/\text{mm}^3

is diagnostic for SBP and requires immediate empiric antimicrobial therapy.

Select appropriate empiric antibiotic therapy.

Intravenous cefotaxime is selected.

Third-generation cephalosporins effectively cover the most common enteric gram-negative organisms and Streptococcus species responsible for community-acquired SBP.

Assess the indications for intravenous albumin administration.

Intravenous albumin is selected as an adjunctive intervention.

The patient meets the high-risk criteria for developing hepatorenal syndrome (HRS) due to a serum creatinine

> 1.0\text{ mg/dL}

and BUN

> 30\text{ mg/dL}

. Albumin expands the effective arterial blood volume and significantly reduces mortality.

Reconcile the patient's home medication list based on the acute presentation.

Oral propranolol is discontinued, and diuretics are held.

Non-selective beta-blockers and diuretics are contraindicated in the setting of SBP with concurrent hypotension and acute kidney injury because they further compromise renal perfusion and precipitate severe hepatorenal syndrome.

Anahtar Kavram

Simultaneous pharmacologic management of Spontaneous Bacterial Peritonitis (SBP) with concomitant acute kidney injury requires empiric antibiotics, intravenous albumin, and the withdrawal of offending home medications like non-selective beta-blockers and diuretics.

Tahmini Süre:2m 0s

Soru 2013Soru →

Match each patient's clinical profile with the most strongly indicated, priority preventive screening intervention based on current national guidelines. Assume all patients are up-to-date on other routine care.

Soldaki öğeye tıklayın, sonra eşleşen sağdaki öğeye tıklayın

Cevabı ve açıklamayı göster

Cevap

The 68-year-old male requires one-time abdominal duplex ultrasonography; the 52-year-old former smoker requires annual low-dose computed tomography; the 42-year-old female requires screening mammography; and the 25-year-old male requires annual STI screening.

Each matched intervention corresponds precisely to current evidence-based thresholds. The 68-year-old meets the age and 'ever-smoker' criteria for an AAA ultrasound. The 52-year-old meets the age, pack-year burden, and timeline criteria for lung cancer LDCT. The 42-year-old meets the updated age criterion for initiating routine mammography. The 25-year-old meets the behavioral risk profile for annual STI screening.

Adım Adım Çözüm

Evaluate the 68-year-old male's screening requirements.

Identify the need for abdominal aortic aneurysm screening.

He falls into the 65-75 age range and meets the criterion of having 'ever smoked' (at least 100 cigarettes lifetime), warranting a one-time ultrasound.

Assess the 52-year-old male's lung cancer risk.

Identify the indication for low-dose computed tomography (LDCT).

He is between 50 and 80 years old, has a smoking history of 20 pack-years or more, and quit less than 15 years ago.

Determine the 42-year-old female's breast cancer screening timeline.

Indicate standard screening mammography.

Her family history of breast cancer at age 65 does not require high-risk early screening, but updated population guidelines stipulate routine screening should begin at age 40.

Review the 25-year-old male's demographic risks.

Indicate comprehensive STI screening.

Guidelines for men who have sex with men emphasize the necessity of at least annual testing for HIV, syphilis, gonorrhea, and chlamydia.

Anahtar Kavram

Age- and risk-stratified application of major USPSTF and CDC preventive screening guidelines.

Soru 2014Soru →

A $54$ -year-old man with acute myeloid leukemia is admitted to the hospital with a fever of $39.4^\circ C$ ( $102.9^\circ F$ ) and chills. He received induction chemotherapy $10$ days ago. His blood pressure is $110/70$ mmHg and heart rate is $112$ /min. Laboratory studies show an absolute neutrophil count of $200/\mu L$ . He has an indwelling central venous catheter in place. Arrange the following steps in the correct chronological sequence for the standard diagnostic evaluation, therapeutic intervention, and longitudinal monitoring of this patient's high-risk febrile neutropenia.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequence is to first obtain blood cultures, immediately follow with empiric broad-spectrum antipseudomonal antibiotics, monitor clinical response and cultures at

48

72

hours, and finally initiate empiric antifungal therapy if fever and severe neutropenia persist beyond

4

7

days.

High-risk febrile neutropenia is a medical emergency requiring a strict, standardized sequential approach. It begins with immediate acquisition of blood cultures (both peripheral and central) to identify the pathogen. Because these patients can deteriorate rapidly from overwhelming bacterial sepsis, this is followed immediately by the administration of empiric broad-spectrum antibiotics covering Pseudomonas aeruginosa (e.g., cefepime). Once therapy is initiated, the patient must be monitored closely, with a structured clinical and microbiological reassessment at the

48

- to

72

-hour mark. If the patient remains persistently febrile and profoundly neutropenic beyond

4

7

days without an identified source, occult fungal infection becomes highly probable, and empiric antifungal therapy (e.g., an echinocandin or azole) is added to the regimen.

Adım Adım Çözüm

Obtain blood cultures before initiating any antibiotics.

Maximizes the chance of identifying the causative bacterial pathogen.

Antibiotic administration prior to culture collection drastically reduces microbiological yield and compromises targeted therapy later.

Administer empiric broad-spectrum antipseudomonal antibiotics.

Provides immediate coverage against high-mortality pathogens like Pseudomonas aeruginosa.

Neutropenic patients lack the normal inflammatory immune response to contain infections, leading to rapid progression to septic shock if untreated.

Reassess clinical status and preliminary culture data at

48

72

hours.

Determines if current empiric therapy is effective or if source control or antibiotic modifications are needed.

It takes approximately

48

72

hours for most standard bacterial cultures to yield preliminary results and for clinical defervescence to occur on appropriate therapy.

Add empiric antifungal therapy at

4

7

days if the patient is still febrile.

Treats potential occult invasive fungal infections.

Prolonged severe neutropenia accompanied by persistent fever unresponsive to broad-spectrum antibacterial agents is a classic presentation for invasive fungal disease.

Anahtar Kavram

Standard management timeline and protocol for high-risk febrile neutropenia.

Soru 2015Soru →

A 61-year-old woman presents to the clinic for a routine health maintenance examination. She feels well and reports no new symptoms. Her medical history is notable for essential hypertension and a total abdominal hysterectomy with bilateral salpingo-oophorectomy performed at age 51 for symptomatic uterine fibroids. She has a 25 pack-year smoking history but successfully quit 16 years ago. Her current medication is amlodipine. Her most recent preventive screenings include a normal colonoscopy at age 53 and a normal screening mammography at age 59. Vital signs today are within normal limits. Physical examination reveals a well-appearing woman with a normal cardiovascular and pulmonary assessment. Which of the following is the most appropriate cancer or disease screening intervention for this patient at today's visit?

Cervical cytology

Dual-energy x-ray absorptiometry

Low-dose computed tomography of the chest

Screening colonoscopy

Screening mammography

Cevabı ve açıklamayı göster

Cevap: Screening mammography

Cevap

Screening mammography is the indicated preventive measure because the patient is due for her biennial breast cancer screening.

The correct answer is screening mammography. According to the United States Preventive Services Task Force (USPSTF), biennial screening mammography is recommended for women aged 40 to 74 years. Because this patient's last mammogram was two years ago at age 59, she is now due for her next screening at age 61.

Adım Adım Çözüm

Evaluate the patient's breast cancer screening status.

The patient is 61 years old and her last mammogram was at age 59.

Current USPSTF guidelines recommend biennial (every 2 years) screening mammography for women aged 40 to 74. Therefore, she is due for a mammogram.

Evaluate the patient's lung cancer screening eligibility.

The patient has a 25 pack-year smoking history but quit 16 years ago.

USPSTF guidelines indicate annual low-dose computed tomography for adults aged 50 to 80 with a 20 pack-year smoking history who currently smoke or quit within the past 15 years. Because she quit 16 years ago, screening is no longer indicated.

Evaluate the patient's cervical cancer screening status.

The patient had a total hysterectomy for benign disease (fibroids) at age 51.

Women who have had their cervix removed for benign indications and do not have a history of high-grade cervical precancer or cervical cancer do not require further cervical cytology screening.

Evaluate the patient's colorectal cancer and osteoporosis screening status.

Last colonoscopy was 8 years ago at age 53. She is 61, and routine DEXA scans begin at age 65.

Average-risk patients with a normal colonoscopy should be rescreened in 10 years (at age 63 for this patient). DEXA is not routinely indicated until age 65 without elevated clinical risk.

Anahtar Kavram

Preventive Care Guidelines in Older Adults

Tahmini Süre:1m 0s

Soru 2016Soru →

A $35$ -year-old man comes to the clinic for follow-up after recently testing positive for human immunodeficiency virus (HIV). He is currently asymptomatic and feels well. Laboratory studies show an absolute CD4 T-lymphocyte count of $145$ cells/mm $^3$ and an HIV viral load of $150,000$ copies/mL. Serum Toxoplasma IgG testing is negative. Antiretroviral therapy is initiated. The physician also plans to prescribe primary prophylaxis against the opportunistic infection for which he is at greatest risk. The patient's medical history is significant for an episode of severe facial angioedema and airway compromise after taking trimethoprim-sulfamethoxazole for a skin infection three years ago. He also has a documented history of glucose-6-phosphate dehydrogenase (G6PD) deficiency, diagnosed after a severe hemolytic episode during a childhood illness. Which of the following is the most appropriate pharmacologic intervention for this patient's primary prophylaxis?

Oral atovaquone

Oral dapsone

Oral trimethoprim-sulfamethoxazole

Oral azithromycin

Oral fluconazole

Cevabı ve açıklamayı göster

Cevap: Oral atovaquone

Cevap

Oral atovaquone is the correct pharmacologic intervention for this patient.

Oral atovaquone is the correct choice. This patient with HIV has a CD4 count of

145

cells/mm

^3

, which is below the threshold of

200

cells/mm

^3

, thereby requiring primary prophylaxis against Pneumocystis jirovecii pneumonia (PCP). The standard first-line therapy is trimethoprim-sulfamethoxazole; however, this patient's history of angioedema and airway compromise constitutes an absolute contraindication to sulfonamides. The standard second-line alternative is dapsone. Because dapsone is an oxidizing agent, it is strictly contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency due to the high risk of precipitating acute hemolytic anemia. Therefore, the most appropriate next-line pharmacologic intervention is oral atovaquone, which is safe and effective for PCP prophylaxis in this scenario.

Adım Adım Çözüm

Identify the primary infectious risk based on immunologic status.

The patient has a CD4 count of

145

cells/mm

^3

(which is

< 200

cells/mm

^3

), placing him at high risk for Pneumocystis jirovecii pneumonia (PCP).

Current guidelines mandate primary prophylaxis against PCP when the CD4 count falls below

200

cells/mm

^3

Evaluate the standard first-line pharmacologic intervention.

Trimethoprim-sulfamethoxazole is the standard first-line agent, but it must be bypassed.

The patient has a history of severe IgE-mediated anaphylaxis (angioedema, airway compromise) to sulfonamides, making its use an absolute contraindication.

Evaluate the standard second-line pharmacologic intervention.

Oral dapsone is the typical second-line agent, but it must also be bypassed.

Dapsone is a strong oxidizing agent. In a patient with known G6PD deficiency, it will precipitate an acute, potentially life-threatening hemolytic anemia.

Select the safest and most effective remaining alternative.

Oral atovaquone (or aerosolized pentamidine) is selected.

Atovaquone effectively prevents PCP and does not cross-react with sulfonamides or trigger oxidative hemolysis in G6PD deficiency.

Anahtar Kavram

In patients requiring PCP prophylaxis who have absolute contraindications to both trimethoprim-sulfamethoxazole (e.g., anaphylaxis) and dapsone (e.g., G6PD deficiency), oral atovaquone or aerosolized pentamidine are the pharmacologic interventions of choice.

Soru 2017Soru →

A 45-year-old male presents to the clinic to establish care. He reports feeling generally well but wants a comprehensive health evaluation as he has not seen a physician in 12 years. His medical history is notable for prior intravenous heroin use, though he has been abstinent for 5 years and is currently maintained on buprenorphine. He has smoked one pack of cigarettes daily for the past 25 years. Vital signs are within normal limits, and his physical examination is unremarkable. Based on current guidelines, which of the following preventive interventions are indicated for this patient at today's visit? (Select all that apply)

Geçerli olan tümünü seçin

Hepatitis C virus antibody testing

Screening colonoscopy

Low-dose computed tomography of the chest

Abdominal aortic aneurysm screening with ultrasonography

Prostate-specific antigen testing

Cevabı ve açıklamayı göster

Cevap: Hepatitis C virus antibody testing; Screening colonoscopy

Cevap

Hepatitis C virus antibody testing and Screening colonoscopy

The patient is 45 years old, which is the current guideline-recommended age to initiate colorectal cancer screening in average-risk individuals. Furthermore, he is within the 18 to 79 age cohort for universal Hepatitis C virus antibody testing, an indication made even stronger by his past intravenous drug use.

Adım Adım Çözüm

Analyze patient demographics and risk factors.

The patient is a 45-year-old male with a 25 pack-year smoking history and a history of intravenous drug use.

Preventive screening guidelines are dictated by age, biological sex, and specific behavioral risk factors.

Evaluate indications for infectious disease screening.

Hepatitis C screening is indicated.

The USPSTF recommends a one-time Hepatitis C screening for all adults aged 18 to 79. His history of IV drug use provides an additional, high-risk indication.

Evaluate indications for cancer screening.

Colorectal cancer screening is indicated, but lung and prostate cancer screenings are not.

Colorectal screening begins at age 45. Low-dose CT for lung cancer requires a 20 pack-year history BUT does not begin until age 50. PSA screening (via shared decision-making) typically begins at age 55.

Evaluate indications for vascular screening.

Abdominal aortic aneurysm (AAA) screening is not indicated.

While the patient has a smoking history, AAA screening with ultrasonography is exclusively recommended for men aged 65 to 75.

Anahtar Kavram

Age-appropriate integration of USPSTF preventive screening guidelines, particularly the updated starting age for colorectal cancer screening (age 45) and the specific age parameters for lung cancer and AAA screening.

Soru 2018Soru →

A male patient in his late sixties presents to the primary care clinic with a three-day history of dysuria, increased urinary frequency, and suprapubic discomfort. His past medical history is significant for a provoked deep vein thrombosis of the right lower extremity diagnosed three months ago, for which he has been receiving warfarin therapy. His International Normalized Ratio (INR) has been stable and therapeutic for the past six weeks. A point-of-care INR obtained today is $2.8$ . Urinalysis reveals positive leukocyte esterase, positive nitrites, and moderate bacteria. The physician diagnoses an uncomplicated urinary tract infection and decides to prescribe a three-day course of oral trimethoprim-sulfamethoxazole. Vital signs are within normal limits, and the patient is otherwise stable.

Which of the following is the most appropriate next step regarding this patient's anticoagulant management?

Continue the current warfarin dose and maintain the routine four-week interval for the next INR check

Measure an activated partial thromboplastin time (aPTT) prior to starting the antibiotic to establish a new baseline

Admit the patient to the hospital for continuous intravenous unfractionated heparin bridging during the antibiotic treatment

Decrease the current warfarin dose by

25\%

50\%

and schedule an INR check in

3

5

days

Hold warfarin therapy for the duration of the antibiotic course to prevent the INR from exceeding the therapeutic range

Cevabı ve açıklamayı göster

Cevap: Decrease the current warfarin dose by $25\%$ to $50\%$ and schedule an INR check in $3$ to $5$ days

Cevap

Decrease the current warfarin dose by

25\%

50\%

and schedule an INR check in

3

5

days.

Trimethoprim-sulfamethoxazole is a potent inhibitor of the cytochrome P450 2C9 (CYP2C9) isoenzyme. Warfarin is administered as a racemic mixture, and its more potent S-enantiomer is primarily metabolized by CYP2C9. When this antibiotic is introduced, warfarin metabolism is rapidly inhibited, leading to elevated serum levels and a supratherapeutic INR, which drastically increases the risk of major bleeding. The standard of care for a patient with a stable INR who must start a strong CYP2C9 inhibitor (such as trimethoprim-sulfamethoxazole, metronidazole, or fluconazole) is to pre-emptively reduce the weekly warfarin dose by

25\%

50\%

and to recheck the INR within

3

5

days. This approach ensures continuous therapeutic anticoagulation while proactively mitigating toxicity.

Adım Adım Çözüm

Identify the pharmacokinetic interaction between trimethoprim-sulfamethoxazole and warfarin.

Trimethoprim-sulfamethoxazole is a strong inhibitor of CYP2C9, the primary enzyme responsible for metabolizing the highly active S-enantiomer of warfarin.

Recognizing specific drug-drug interactions is required to anticipate their clinical effects on patient physiology.

Determine the expected clinical consequence of this specific drug-drug interaction.

Inhibition of warfarin metabolism will increase its serum concentration, leading to a supratherapeutic INR and a significantly elevated risk of bleeding.

Anticipating the adverse outcome dictates the necessity of a preventive intervention.

Select the appropriate clinical protocol for monitoring and treatment adjustment.

Empirical pre-emptive dose reduction of warfarin combined with early laboratory reassessment is the standard of care.

This strategy safely balances the need for continuous therapeutic anticoagulation against the imminent risk of drug-induced toxicity.

Anahtar Kavram

Empiric dose reduction and close INR monitoring when initiating strong CYP2C9 inhibitors in patients on warfarin.

Tahmini Süre:1m 0s

Soru 2019Soru →

A 68-year-old man is admitted to the intensive care unit with severe community-acquired pneumonia, altered mental status, and oliguria. His temperature is $39.2^\circ\text{C}$ ( $102.6^\circ\text{F}$ ), heart rate is $128$ /min, and respiratory rate is $28$ /min. Initial blood pressure is $72/40$ mm Hg, corresponding to a mean arterial pressure (MAP) of $50$ mm Hg. Peripheral pulses are weak, and capillary refill time is prolonged. Blood cultures and sputum cultures are drawn, and empiric broad-spectrum intravenous antibiotics are administered promptly. However, he remains persistently hypotensive with poor peripheral perfusion.

Arrange the following interventions in the correct guideline-directed sequential order for the management of this patient's shock. Assume the patient's MAP remains below the target of $65$ mm Hg despite the optimal titration of each preceding intervention.

Öğeleri doğru sıraya koymak için sürükleyin

Cevabı ve açıklamayı göster

Cevap

The correct sequential order for managing septic shock is: intravenous balanced crystalloids, followed by norepinephrine, followed by vasopressin, and finally intravenous hydrocortisone.

The Surviving Sepsis Campaign guidelines recommend a specific stepwise approach to hemodynamic optimization in septic shock. First, immediate fluid resuscitation with

30

mL/kg of crystalloids is necessary to restore preload. If hypotension (MAP

< 65

mm Hg) persists after fluids, norepinephrine is the first-line vasopressor. If the MAP target is still not met, vasopressin (typically at

0.03

units/min) is added as a second-line agent to augment mean arterial pressure and reduce the required norepinephrine dose. Finally, for shock that is refractory to adequate fluid loading and multiple vasopressors, intravenous hydrocortisone is administered to treat suspected critical illness-related corticosteroid insufficiency.

Adım Adım Çözüm

Identify the patient's condition

The patient is experiencing septic shock due to severe pneumonia, indicated by profound hypotension (MAP of

50

mm Hg) and signs of end-organ dysfunction.

Recognizing the etiology of shock is critical for applying the correct treatment algorithm.

Determine the initial resuscitative step

Rapid administration of

30

mL/kg of balanced crystalloids is required.

Intravenous fluids are the mandatory first step to correct absolute or relative hypovolemia and optimize preload before initiating vasoactive medications.

Select the first-line vasopressor

Initiate continuous intravenous norepinephrine.

Current guidelines designate norepinephrine as the first-line vasoactive agent for patients whose MAP remains below

65

mm Hg despite adequate fluid resuscitation.

Determine the second-line escalation therapy

Add continuous intravenous vasopressin.

Vasopressin is added to augment MAP and decrease the required dosage of norepinephrine, mitigating catecholamine-induced toxicity.

Select therapy for refractory shock

Administer intravenous hydrocortisone.

For patients with refractory shock who remain hypotensive despite fluids and escalating doses of vasopressors, intravenous hydrocortisone at a stress dose of

200

mg/day is recommended.

Anahtar Kavram

The stepwise pharmacologic escalation in septic shock prioritizes fluid resuscitation, followed by norepinephrine, then vasopressin, and finally corticosteroids for refractory cases.

Soru 2020Soru →

A 26-year-old primigravid woman at 9 weeks gestation is brought to the emergency department by her husband due to severe agitation, fever, and palpitations. She has been experiencing intractable nausea and vomiting for the past two weeks. On presentation, she is confused and restless. Temperature is $39.4^\circ\text{C}$ ( $102.9^\circ\text{F}$ ), blood pressure is $150/65\text{ mmHg}$ , pulse is $148/\text{min}$ and irregularly irregular, and respiratory rate is $24/\text{min}$ . Physical examination reveals a diffusely enlarged, non-tender thyroid gland, a fine resting tremor, warm and moist skin, and hyperreflexia. Electrocardiogram confirms atrial fibrillation with rapid ventricular response. Laboratory studies show:

Thyroid-stimulating hormone (TSH): $<0.01\text{ \mu U/mL}$
Free thyroxine (T4): $5.8\text{ ng/dL}$ (Reference: $0.8-2.0\text{ ng/dL}$ )
Liver function tests: Within normal limits

Which of the following pharmacologic interventions should be included in the immediate management of this patient? (Select all that apply)

Geçerli olan tümünü seçin

Oral propylthiouracil

Intravenous hydrocortisone

Oral methimazole

Oral aspirin

Intravenous potassium iodide administered simultaneously with thionamides

Cevabı ve açıklamayı göster

Cevap: Oral propylthiouracil; Intravenous hydrocortisone

Cevap

The appropriate immediate interventions for this pregnant patient in thyroid storm are oral propylthiouracil and intravenous hydrocortisone.

The correct interventions are propylthiouracil and hydrocortisone. Propylthiouracil is the thionamide of choice during the first trimester of pregnancy to block the synthesis of new thyroid hormone and decrease peripheral conversion of T4 to T3, while avoiding the teratogenic risks of methimazole. Intravenous hydrocortisone is indicated to further reduce peripheral T4 to T3 conversion and provide coverage for relative adrenal insufficiency triggered by the hypermetabolic crisis.

Adım Adım Çözüm

Diagnose the patient's acute condition based on clinical presentation and laboratory findings.

The patient has fever, tachycardia, agitation, a goiter, and markedly elevated free T4 with suppressed TSH, confirming a diagnosis of thyroid storm. She is also in her first trimester of pregnancy.

Accurate identification of both the endocrine emergency (thyroid storm) and the patient's specific physiological state (first trimester pregnancy) is essential to select safe and effective pharmacotherapy.

Select an antithyroid drug that is safe in early pregnancy to block hormone synthesis.

Propylthiouracil is selected over methimazole.

Propylthiouracil is preferred in the first trimester to avoid methimazole-induced embryopathy (e.g., aplasia cutis). It additionally blocks the peripheral conversion of T4 to T3.

Identify supportive pharmacotherapy to reduce active hormone levels and provide systemic support.

Intravenous hydrocortisone is selected.

Glucocorticoids inhibit peripheral deiodination of T4 to active T3 and treat potential relative adrenal insufficiency resulting from accelerated cortisol metabolism in thyroid storm.

Exclude contraindicated interventions that would worsen the thyrotoxicosis or harm the fetus.

Aspirin, methimazole, and simultaneous iodine administration are excluded.

Aspirin displaces T4 from binding proteins; methimazole is teratogenic in the first trimester; and iodine given before thionamide blockade fuels further hormone synthesis.

Anahtar Kavram

Management of Thyroid Storm in Pregnancy

ÖncekiSayfa 101 / 104Sonraki

Patient Management

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram

Sık Yapılan Hatalar

Cevap

Adım Adım Çözüm

Anahtar Kavram